Peer-reviewed veterinary case report
Heart damage signs in dogs during doxorubicin cancer treatment
By Surachetpong, Sirilak Disatian et al.·Published in The Japanese journal of veterinary research·2016·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Serial measurements of cardiac troponin I (cTnI) in dogs treated with doxorubicin.
- Species:
- dog
Plain-English summary
A group of dogs with cancer were monitored for heart health while receiving a chemotherapy drug called doxorubicin. The dogs showed increased levels of cardiac troponin I (cTnI), a protein that indicates heart stress, after several weeks of treatment. This increase in cTnI levels happened before any noticeable changes in heart function were seen on ultrasound tests. The findings suggest that measuring cTnI can help veterinarians detect heart problems early in dogs undergoing doxorubicin therapy.
People also search for: dog cancer treatment heart problems · doxorubicin side effects dogs · elevated troponin levels in dogs
Abstract
The study aimed to evaluate whether cardiac troponin I (cTnI) and pulsed-wave tissue Doppler imaging (TDI) measurements can detect cardiac changes during doxorubicin therapy in dogs with various types of cancers compared to conventional echocardiography. Serial measurements of cTnI and conventional and pulsed-wave TDI echocardiography were performed in 12 dogs diagnosed with various types of cancers at day 0, weeks 3, 6, 9, and 12 prior to each doxorubicin injection. After treatment with doxorubicin, dogs had significantly increased cTnI levels at week 9 (p = 0.027) and 12 (p = 0.027) compared to normal untreated dogs. Dogs had increased cTnI levels during doxorubicin therapy (p = 0.004). Percent left ventricular ejection fraction (LVEF) and fractional shortening (FS) assessed by 2-dimensional and M-mode echocardiography significantly decreased at weeks 9 and 12. Pulsed-wave TDI derived myocardial performance index (MPI) increased significantly at weeks 9 and 12 compared to day 0 (p = 0.028 and 0.040, respectively). In conclusion, dogs treated with doxorubicin had increased cTnI levels. An increase in cTnI levels was detected before echocardiographic value changes. Serum cTnI can be a sensitive marker for detection of cardiotoxicity in dogs treated with doxorubicin.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/29786172/